Project Details
| Status | Active |
|---|---|
| Effective start/end date | 3/1/18 → 12/31/24 |
Funding
- Alexion Pharmaceuticals, Inc (Prot#WTX101 // Prot#WTX101)
- Wilson Therapeutics AB (Prot#WTX101 // Prot#WTX101)
Prot#WTX101-301: A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older with an Extension Phase of up to 60 Mont
- Bega, Danny (PD/PI)
Project: Research project